The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

Only 13% of oncology trial press releases from major pharma companies include precise data — raising concerns about ...

Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into ...

MPox is endemic in DRC, and has continued to cause large numbers of cases in the WHO African Region. In April, 2025, the WHO has restated that MPox continues to be a Public Health Emergency of ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.

Families report devastating outcomes following Librela injections for dogs, citing paralysis and death. Meanwhile, Zoetis maintains side effects are rare.

Inozyme recently featured new clinical insights and hosted an educational symposium at the Joint Congress of the European ...